Genedrive (GB:GDR) has released an update.
Don't Miss Our New Year's Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Genedrive PLC has reported significant advances in its pharmacogenetic testing products, with revenues reaching £0.5 million and a successful £6 million equity fundraise. The company received positive endorsements from NICE and the FDA, and its products are now being used in the UK and overseas. With a strong cash position and ongoing market expansion efforts, Genedrive is poised for growth in 2025.
For further insights into GB:GDR stock, check out TipRanks’ Stock Analysis page.
